The entero-insular axis: Implications for human metabolism

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 1, 2008, Pages 43-56

  Ranganath, Lakshminarayan R ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

cells; Adipose tissue; Bone; Brain; Diabetes; Dipeptidyl peptidase IV (DPPIV); Exendin 4; Glucagon like peptide 1 (GLP 1); Glucose; Glucose dependent insulinotropic polypeptide (GIP); Incretins; Insulin; Liver; Metabolism

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; SOMATOSTATIN; SULFONYLUREA;

ADIPOSE TISSUE; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; APOPTOSIS; BRAIN REGION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIABETES CONTROL; DIGESTIVE FUNCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG HALF LIFE; ENZYMATIC DEGRADATION; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE RELEASE; HUMAN; INJECTION SITE REACTION; INSULIN RELEASE; INSULIN SENSITIVITY; METABOLIC REGULATION; MOLECULAR WEIGHT; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL ASSESSMENT; OBESITY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; STOMACH EMPTYING; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANTIGENS, CD26; BLOOD GLUCOSE; BRAIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; LIVER; MOLECULAR SEQUENCE DATA; UNITED STATES;

ANIMALIA;

EID: 38349064999     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.008     Document Type: Review

References (125)

1. Moore B, Eddie ES, Abram JH. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J 1906;1:28-38.
2. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-1.
3. Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 1971;49:867-72.
4. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716-8.
5. Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide 1, an insulin releasing hormone from the distal gut. FEBS Lett 1987;211:169-74.
6. Creutzfeldt W, Ebert R. The incretin concept. Adv Metab Disord 1988;11:333-67.
7. Habener JF. The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 1993;22:775-94.
8. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995;16:390-410.
9. Alam MJ, Buchanan KD. Conflicting gastric inhibitory polypeptide data: possible causes. Diabetes Res Clin Pract 1993;19:93-101.
10. Morgan LM. Insulin secretion and the enteroinsular axis. In: Flatt PR, editor. Nutrient regulation of insulin secretion. London: Biochemical Society, Portland Press, 1992: 1-22.
11. Ranganath L, Sedgwick I, Morgan L, Wright J, Marks V. The ageing entero-insular axis. Diabetologia 1998;41:1309-13.
12. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type II diabetic patients and healthy subjects. Diabetes 1995;44:1126-31.
13. Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF. A guardian angel: the involvement of the dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci 2000;99:93-104.
14. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci 2005;108:277-92.
15. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its antihyperglycaemic effect. Diabetes Med 1998;15:120-4.
16. Ranganath L, Morgan L. An osmotic stimulus-mediating glucagon-like peptide-1 (7-36Amide) (GLP-1) secretion in acarbose-induced sucrose malabsorption? Nutrition 2000;16:64-5.
17. Ranganath L, Norris F, Morgan L, Wright J, Marks V. The effect of circulating non-esterified fatty acids on the entero-insular axis. Eur J Clin Invest 1999;29:27-32.
18. Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D, et al. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1(7-36 amide) (GLP-1). Diabetes Metab Res Rev 1999;15:390-4.
19. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138:159-66.
20. Lu M, Wheeler MB, Leng XH, Boyd AE III. Stimulation of insulin secretion and insulin gene expression by gastric inhibitory polypeptide. Trans Assoc Am Physicians 1993;106:42-53.
21. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998;47:57-65.
22. Wang Y, Montrose-Rafizadeh C, Adams L, Raygada M, Nadiv O, Egan JM. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol Cell Endocrinol 1996;116:81-7.
23. Kim SJ, Choi WS, Han JS, Warnock G, Fedida D, McIntosh CH. A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis. J Biol Chem 2005;280:28692-700.
24. Light PE, Manning Fox JE, Riedel MJ, Wheeler MB. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol 2002;16:2135-44.
25. MacDonald PE, Salapatek AM, Wheeler MB. Glucagon-like peptide-1 receptor activation antagonizes voltagedependent repolarizing K(+) currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002;51:S443-7.
26. Sasaki S, Nakagaki I, Kondo H, Hori S. Involvement of the ryanodine-sensitive Ca2+ store in GLP-1-induced Ca2+ oscillations in insulin-secreting HIT cells. Pflugers Archiv Eur J Physiol 2002;445:342-51.
27. Kwan EP, Gaisano HY. Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells. Diabetes 2005;54:2734-43.
28. Srinivasan M, Aalinkeel R, Song F, Lee B. Laychock SG. Patel MS. Adaptive changes in insulin secretion by islets from neonatal rats raised on a high-carbohydrate formula. Am J Physiol Endocrinol Metab 2000; 279:E1347-57.
29. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, et al. Glucagon-like peptide-1 improves the ability of the B-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 1998;47:1259-65.
30. Delmeire D, Flamez D, Hinke SA, Cali JJ, Pipeleers D, Schuit F. Type VIII adenylyl cyclase in rat beta cells: coin cidence signal detector/generator for glucose and GLP-1. Diabetologia 2003;46:1383-93.
31. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene. Nat Med 1996;2:1254-8.
32. Hansen L, Holst JJ. The two intestinal incretins differentially regulate glucagon secretion due to differing intraislet paracrine effects. In: Program and Abstracts of the European Association for the Study of Diabetes, 41st Annual Meeting, September 12-15, 2005, Athens, Greece. Abstract 163.
33. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 1995;38:720-5.
34. de Heer J, Hoy MK, Holst JJ. GLP-1, but not GIP, inhibits glucagon secretion via somatostatin in the perfused rat pancreas. In: Program and Abstracts of the European Association for the Study of Diabetes, 41st Annual Meeting, September 12-15, 2005, Athens, Greece. Abstract 164.
35. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-71.
36. Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1. Horm Metab Res 2004;36:811-21.
37. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old glucose-intolerant rats. Endocrinology 2000;141:4600-5.
38. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-71.
39. Wideman RD, Kieffer TJ. Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. Horm Metab Res 2004;36:782-6.
40. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002;174:233-46.
41. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005;280:22297-307.
42. Simonsson E, Karlsson S, Ahren B. The cyclic AMP-protein kinase A pathway restrains islet phospholipase A(2) activation. Biochem Biophys Res Commun 2000;269:242-6.
43. Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006;188:481-92.
44. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001;15:1559-70.
45. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-6.
46. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991;130:267-72.
47. Ruiz-Grande C, Alarcon C, Merida E, Valverde I. Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 1992;13:13-6.
48. Ranganath L, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996;38:916-19.
49. Gama R. Norris F. Morgan L, Hampton S, Wright J, Marks V. Elevated post-prandial gastric inhibitory polypeptide concentrations in hypertriglyceridaemic subjects. Clin Sci 1997;93:343-7.
50. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979;28:1141-2.
51. Eckel RH, Fujimoto WY, Brunzell JD. Effect of in-vitro lifespan of 3T3-L1 cells on hormonal responsiveness of lipoprotein lipase activity. Int J Obesity 1981;5:571-7.
52. Lui EY, Asa SL, Drucker DJ, Lee YC, Brubaker PL. Glucagon and related peptides in fetal rat hypothalamus in vivo and in vitro. Endocrinology 1990;126:110-17.
53. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002;18:7-14.
54. Ranganath L, Daousi C, Cleator J, Pinkney J, Wilding JP. Effects of GLP-1 and GIP on energy expenditure and appetite in type 2 diabetes. Ann Clin Biochem (National Meeting) 2007;44:T25.
55. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52.
56. Kinzig KP, Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003;23:6163-70.
57. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-9.
58. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881-8.
59. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-66.
60. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003;72:603-12.
61. Perry T, Greig NH. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 2002;4:487-96.
62. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005;2:377-85.
63. Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, et al. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann NY Acad Sci 2004;1035:290-315.
64. Richter G, Goke R, Goke B, Schmidt H, Arnold R. Characterisation of glucagon-like peptide-1(7-36)amide receptors of rat lung membranes by covalent cross-linking. FEBS Lett 1991;280:247-50.
65. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000;141:1228-35.
66. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab 2007;292:E543-8.
67. Christgau S, Bitsch-Jensen O, Hanover-Bjarnson N, Gamwell-Henriksen E, Qvist P, Alexandersen P, et al. Serum crossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505-11.
68. Bjarnson NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone 2002;30:307-13.
69. Henriksen DB, Alexandersen P, Bjarnson NH, Vilsboll T, Hartmann B, Henriksen EE, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Min Res 2003;18:2180-9.
70. Patil T, Ali F, Zia A, Rowbottom L, Durham B, Dutton J, et al. Nutritional and hormonal influences on bone metabolism in healthy individuals. Ann Clin Biochem (National Meeting) 200602.
71. Rowbottom L, Patil T, Ali F, Zia A, Jennings R, Dutton J, et al. Is a decrease in circulating C-terminal telopeptide (CTx) following intravenous glucose and GLP-1 due to increased renal excretion? Ann Clin Biochem (National Meeting) 200603.
72. Ranganath L, Mishra V, Patil T, Ali F, Zia A, Jennings R, et al. Renal handling of circulating C-terminal telopeptide in health following intravenous glucose and GLP-1. Ann Clin Biochem (National Meeting) 2007;44:W12.
73. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006;20:1644-51.
74. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Cardiac Failure 2006;12:694-9.
75. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006;317:1106-13.
76. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289:H2401-8.
77. Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diabetes Vasc Dis Res 2004;1:40-3.
78. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242-52.
79. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001;89:445-52.
80. Rizza R, Verdonk C, Miles J, Service FJ, Gerich J. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. J Clin Invest 1979;63:1119-23.
81. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med 1981;304:1518-24.
82. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 2000;133:73-4.
83. Hawkins D, Bradberry JC, Cziraky MJ, Talbert RL, Bartels DW, Cerveny JD. National pharmacy cardiovascular council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 2002;22:436-44.
84. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
85. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004;53:S190-96.
86. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabetes Med 2000;17:713-19.
87. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educator 2006;32:910-7.
88. Chaudhry ZW, Gannon MC, Nuttall FQ. Stability of body weight in type 2 diabetes. Diabetes Care 2006;29:493-7.
89. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33-47.
90. U.K. Prospective Diabetes Study Group 16. Overview of 6 years therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-58.
91. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-44.
92. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18.
93. Horowitz M, Dent J, Fraser R, Sun W, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994;39:S7-13.
94. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 1992;33:1496-500.
95. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-15.
96. Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970;49:837-48.
97. Ahren B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 2001;44:1998-2003.
98. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalisation of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4.
99. Toft-Nielsen MB, Dambolt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.
100. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206.
101. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like pep tide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci 1999;96:335-42.
102. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-13.
103. Herman G, Zhao PL, Dietrich B, Prior TW, Lo WD, Atkin JF, et al. The DPP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. Diabetes 2004;53(Suppl 2):A82.
104. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741-50.
105. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84.
106. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Therap 2006;28:1556-68.
107. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-9.
108. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.
109. Nauck M, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006;114:417-23.
110. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004;53:2397-403.
111. Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobson J, Bodil E. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes 2003;52:A128.
112. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88.
113. Amylin Pharmaceuticals, Inc. Byetta (exenatide) package insert. San Diego, CA, 2005. www.byetta.com.
114. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
115. DeFronzo RA, Ratner R, Han J, Kim D, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes mellitus. Diabetes Care 2005;28:1092-100.
116. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
117. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004;20:411-7.
118. Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metabol 2005;90:5991-7.
119. Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metabol Res 2005;37:627-32.
120. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week's treatment with the longacting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.
121. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-8.
122. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Therap 2006;28:1556-68.
123. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000;141:1936-41.
124. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obesity 1999;23:304-11.
125. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, et al. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301.